ImmunoCellular Therapeutics Announces Issuance of Japanese Patent Covering Its Lead Antibody Product Candidate ICT-109 For Treatment of Small Cell Lung Cancer

LOS ANGELES--(Business Wire)--
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology
company that is developing immune based therapies for the treatment of brain and
other cancers, announced today the issuance of a Japanese patent relating to the
company`s monoclonal antibody therapeutics. Patent No. 4287147, entitled
"Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment
of Small Cell Lung Cancer," covers the use of IMUC`s proprietary antibodies in
diagnosing and treating patients with small cell lung cancer (SCLC) using the
company`s lead antibody product candidate, ICT-109. This latest issuance builds
on IMUC`s existing patent portfolio in U.S. and international jurisdictions for
both the detection and treatment of multiple types of cancer.

"This latest patent provides additional support to our existing network of
intellectual property assets and should serve to position our portfolio of
proprietary antibody therapies extremely well as we continue to actively seek
partnership opportunities both domestically and abroad," commented Manish Singh,
Ph.D., president and chief executive officer of IMUC. "The Japanese patent
office`s recognition of the unique nature of the potential therapeutic benefits
of our antibody technology for early diagnosis and targeted treatment of SCLC
should further enable us to attract partners to assist in bringing these
promising technologies through clinical testing and on to commercialization."

IMUC`s portfolio includes several monoclonal antibody-related technologies
acquired from Molecular Discoveries, LLC, with ICT-109 being a promising
candidate for clinical development thanks to its ability to recognize unique
glycoproteins present on malignant small cell lung cancers. Encouraging
preliminary pre-clinical data generated by IMUC demonstrates in-vivo targeting
by ICT-109 to cells expressing target antigen and efficacy in xenograft models,
making it a good candidate for targeting SCLC. IMUC is targeting having ICT-109
enter clinical trials in 2010 for SCLC and pancreatic cancer indications pending
completion of pre-clinical development work and securing support from a
corporate partner or licensee. It is currently in pre-clinical development, with
plans to couple it with a diagnostic kit to prescreen patients for the specific
antigens that bind to ICT-109, further increasing its potential as a therapeutic
option for these terrible diseases.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune
based therapies for the treatment of brain and other cancers. IMUC expects its
"off the shelf" therapeutic vaccine product candidate targeting cancer stem
cells for multiple cancer indications to enter clinical trials for brain cancer
in early 2010. IMUC is in pre-clinical development of a monoclonal antibody
product candidate for the treatment of small cell lung cancer and pancreatic
cancer, and is also evaluating its platform technology for monoclonal antibody
discovery using differential immunization for diagnosing and treating multiple
types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject
to a number of risks and uncertainties, including without limitation the risk
that patents issued for IMUC`s monoclonal antibody product candidates may not be
enforceable or may not provide commercially significant protection for these
candidates; the need to confirm preliminary pre-clinical data for IMUC`s lead
monoclonal antibody and other monoclonal antibody product candidates; the risks
associated with pre-clinical and clinical development of molecular antibody and
other product candidates; the need for substantial additional capital to fund
development of product candidates beyond their initial clinical or pre-clinical
stages; and the potential inability to secure corporate partners or licensees
for development of the monoclonal antibody product candidates. Additional risks
and uncertainties are described in IMUC`s most recently filed SEC documents,
such as its most recent annual report on Form 10-K, all quarterly reports on
Form 10-Q and any current reports on Form 8-K, IMUC undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.

CEOcast, Inc. for ImmunoCellular Therapeutics
Gary Nash, 212-732-4300
Gnash@ceocast.com

Copyright Business Wire 2009